Endocrine and paracrine characteristics of neuroendocrine prostate cancer

Tarana Arman1 and Peter S. Nelson1,2*

1Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, United States, 2Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, United States

Prostate cancer is a common malignancy affecting men worldwide. While the vast majority of newly diagnosed prostate cancers are categorized as adenocarcinomas, a spectrum of uncommon tumor types occur including those with small cell and neuroendocrine cell features. Benign neuroendocrine cells exist in the normal prostate microenvironment, and these cells may give rise to primary neuroendocrine carcinomas. However, the more common development of neuroendocrine prostate cancer is observed after therapeutics designed to repress the signaling program regulated by the androgen receptor which is active in the majority of localized and metastatic adenocarcinomas. Neuroendocrine tumors are identified through immunohistochemical staining for common markers including chromogranin A/B, synaptophysin and neuron specific enolase (NSE). These markers are also common to neuroendocrine tumors that arise in other tissues and organs such as the gastrointestinal tract, pancreas, lung and skin. Notably, neuroendocrine prostate cancer shares biochemical features with nerve cells, particularly functions involving the secretion of a variety of peptides and proteins. These secreted factors have the potential to exert local paracrine effects, and distant endocrine effects that may modulate tumor progression, invasion, and resistance to therapy. This review discusses the spectrum of factors derived from neuroendocrine prostate cancers and their potential to influence the pathophysiology of localized and metastatic prostate cancer.

KEYWORDS
prostate cancer, secretion, paracrine, endocrine, neuroendocrine

Introduction

Prostate cancer (PC) is the second most commonly diagnosed cancer worldwide among men (1). The American Cancer Society has estimated that ~270,000 men will be diagnosed with PC in 2022 in the United States and PC will cause in excess of 34,000 deaths (2). The vast majority of men diagnosed with PC present with localized disease and the histology of these tumors are primarily adenocarcinomas with distinctive
architectures codified as Gleason patterns (3). The most characteristic feature displayed by the vast majority of localized and metastatic PCs involves the expression of the androgen receptor (AR) and a program of genes/proteins regulated by the AR including a group of secreted factors such as prostate specific antigen (PSA) (4). In addition to specifying prostate epithelial lineage and regulating metabolic and secretory functions, the AR serves as a key therapeutic target both for localized tumors and metastases (5, 6).

While the vast majority of PCs are adenocarcinomas with secretory epithelial features and an active AR program, PCs with a spectrum of other histological characteristics also occur. Among these are PCs with qualities of neuroendocrine (NE) cells (7). These prostate neuroendocrine carcinomas (NEPCs), representing <1% of all localized PCs, exhibit features found in benign NE cells and in NE carcinomas arising in other organs and tissues (8, 9). In the context of localized NEPC, the origin of these tumors has not been conclusively established as they may arise from resident benign NE cells or from stem-like, basal or luminal cells that usually serve as the cell of origin for typical adenocarcinoma (10–12). In the setting of metastatic PC (mPC), tumors with NE features are more common, ranging from 10–30% depending on the markers used for classification and the disease state with respect to the application of therapeutics that suppress AR signaling (13, 14). Preclinical models have demonstrated the occurrence of transdifferentiation whereby tumor cells with a typical epithelial phenotype and active AR program lose AR activity and gain NE characteristics during the development of resistance to AR repression (15–17). With the advent of more potent AR signaling inhibitors (ARSI) such as abiraterone and enzalutamide, the frequency of tumors with NE phenotypes is increasing (18). One feature of metastatic NEPC is the downregulation or complete absence of AR expression and AR signaling (18, 19). Notably, since a subset of these tumors harbor underlying genomic alterations commonly observed in AR-active PCs that serve to promote AR oncogenic functions such as TMPRSS2-ERG rearrangements and structural alterations in the AR locus – it is likely that these metastatic PCs arise through transdifferentiation processes that are usually repressed by an active AR program, and enhanced by the loss of key tumor suppressors that influence cell reprogramming such as TP53 and RBAI (13, 19–25).

While pure NEPC is evident in some tumor biopsies including a subset with small cell histology that is indistinguishable from small cell carcinomas arising in other organs such as the lung, other tumors show mixtures of ARPC and NEPC cells indicating a degree of intratumor heterogeneity (14, 26). Currently, neuroendocrine small cell carcinomas are primarily characterized by morphological features, lack of AR expression, and a higher expression of several canonical markers that reflects NE cell differentiation, e.g. the transcriptional factors (TFs) ASCL1, NEUROD1, INSM1, and NE function, for example, the secreted proteins synaptophysin (SYP), chromogranin A (CgA) and neuron specific enolase (NSE) (14, 27, 28).

The role of the TFs in NE differentiation has been an active area of investigation. ASCL1 plays a key role in promoting and maintaining NE features of luminal cell types by modulating chromatin dynamics, supporting lineage plasticity, and directly regulating the expression of secreted NE proteins (29). Similarly, NEUROD1 has been studied in the context of several aggressive neural/neuroendocrine carcinomas and are important for their survival, invasion, and metastasis (30). INSM1 is a zinc-finger transcriptional factor that functions as a transcriptional repressor, thus regulating cell cycle arrest and facilitating NE differentiation (31). On the other hand, endocrine and paracrine functions of NE secretory proteins, despite being some of the most commonly used NE markers have not been established. Most of these canonical markers are not specific to the prostate, but are rather expressed in a variety of tumors that belong to the diffuse neuroendocrine system (32).

**Characteristics of neuroendocrine cells in the normal prostate and prostate carcinoma**

The prostate is a complex secretory organ comprised of multiple cell types broadly partitioned into epithelium and stroma. The stroma includes predominant resident cell types of smooth muscle, fibroblasts, vascular endothelium and nerves, which are variably infiltrated with transitory inflammatory cell populations that include neutrophils, lymphocytes, and macrophages (33–35). The epithelial compartment is comprised of two primary cell types: basal and luminal/secretory cells, and a minor (<1%) population of neuroendocrine (NE) cells (7, 10, 12, 36) (Table 1). Increasingly sophisticated molecular profiling studies now subdivide these broadly classified types into subtypes with distinctive functions such as those with stem cell/self-renewal capabilities (35, 46, 47). The rare resident NE cells are not easily appreciated using standard H&E staining. They are better identified through immunohistochemistry (IHC) using common markers including chromogranin A (CgA), Synaptophysin (SYP), neuron-specific enolase (NSE), neural cell adhesion molecule (NCAM), Forkhead-box A2 (FOXA2) and CXC chemokine receptor 2 (CXCRI2) (12, 48). NE cells are androgen-insensitive and postmitotic and have been shown to be preferentially situated around Ki-67 positive epithelial cells (49, 50), which are highly proliferative. Morphologically, there are two distinct populations of NE cells in the prostate: open, flask-shaped cells with long and slender extensions reaching the lumen, and closed cells without luminal extensions (51) (Figure 1). Although the distinct roles of these two NE sub-populations have not been addressed specifically, there is a
distinction in their ability to interact with the prostate environment. Closed cells can only receive basal stimuli, whereas, open cells can also receive luminal stimuli (52). The functional role of NE cells in the mature prostate is not well-defined. Electron microscopic studies have shown that NE cells secrete a variety of products, including serotonin, histamine, chromogranin A and other related peptides, calcitonin, calcitonin gene-related peptide, kavalactin, neuropeptide Y, vasoactive intestinal peptide (VIP), bombesin/gastrin releasing peptide (GRP), somatostatin, alpha-human chorionic gonadotropin (aHCG), parathyroid hormone-related protein (PTHrP), thyroid stimulating hormone-like peptide, cholecystokinin, adrenomedullin and vascular endothelial growth factor (VEGF) (8, 53). The potential role of these factors on prostate cancer pathobiology has been detailed in Table 2, however, in normal physiology these secreted factors have growth promoting and angiogenic properties, justifying the proximity of NE cells near to the highly proliferative cells. The receptors for some of these products are detected in benign and neoplastic prostate epithelium. This suggests, the possible roles of NE cells in the regulation of growth and differentiation of the developing prostate and also regulation of secretory processes in the mature gland (8, 51, 53).

### Table 1: Common cell types comprising the normal prostate.

| Cell type          | Markers for identification | Function                                                                 | References |
|--------------------|-----------------------------|--------------------------------------------------------------------------|------------|
| Smooth Muscle Cells| • ACTA2, MYH11, MT1A, RG55   | • Contractile function altering prostate glandular shape for urination vs ejaculation. | (37, 38)   |
|                    | • Identified by a combination of morphology, tissue position and lack of markers for epithelial cells, endothelial cells and leukocytes. | • Structural component of the stroma.                                    |            |
|                    | • Vimentin                  |                                                                          |            |
| Fibroblast Cells   | • APOD, FBLN1, PTGDS, DCN   | • Production of extracellular matrix                                       | (35)       |
|                    | • Vimentin                  | • Structural component of stroma                                          |            |
| Vascular Endothelial Cells | • VEGF          | • Production of signaling molecules that influence epithelial development and function |            |
| Nerves and Nerve Cells | • Protein S100 | • Receives sympathetic input via hypogastric nerves.                     | (41)       |
| Neutrophils        | • CD16                      | • Receives parasympathetic input via pelvic nerve.                        |            |
|                    | • CD45                      | • These nerves also provide sensory inputs to the gland.                  |            |
|                    | • VEGF                      | • Role in tumor development by producing cytokines, proteases, and reactive oxygen species (ROS) and interacting with other immune cells | (42)       |
| Lymphocytes        | • CD3                       | • Growth and maintenance of differentiation of prostatic epithelium.      | (39, 40)   |
| Macrophages        | • CD4                       | • Critical components of antitumor immunity.                              | (42)       |
|                    | • CD19                      | • Aid in antibody production.                                            |            |
|                    | • CD206                     | • Promotes cell proliferation of normal prostate epithelial cells.        | (43)       |
| Basal Epithelial Cells | • Cytokeratins 5 and 14 | • Critical role in maintaining ductal integrity.                          | (44)       |
|                    | • p63                       | • Maintenance of survival of luminal cells.                               |            |
| Luminal/Secretory Epithelial Cells | • CD26, CD38 | • Prostate development.                                                 | (45)       |
|                    | • KLK3                      | • Androgen mediated regeneration.                                        |            |
|                    | • Androgen receptor (AR)    |                                                                          |            |
|                    | • Prostate specific antigen (PSA) |                                                                  |            |
| Neuroendocrine Cells | • CGA                      | • Function not well studied.                                             | (12)       |
|                    | • SYP                       | • Interacts with nearby epithelial cells in a paracrine manner.           |            |
|                    | • NSE                       |                                                                          |            |
|                    | • NCAM/CD56)                |                                                                          |            |
|                    | • FOXA2                     |                                                                          |            |
|                    | • CXCR2                     |                                                                          |            |
Neuroendocrine prostate cancer and neuroendocrine transdifferentiation

Detailed mechanisms influencing prostate carcinogenesis and tumor development have been previously reviewed (93, 94). Briefly, invasive prostate adenocarcinoma may develop directly from differentiated secretory epithelium, epithelium with stem-like characteristics, or from precursor lesions such as high grade prostatic intraepithelial neoplasia (HGPIN). Prostate adenocarcinoma exhibits characteristic features that include cytologic atypia with enlargement of nuclei and nucleoli, loss of the basal cell layer, branching morphogenesis, and ultimately loss of gland formation (93–95). While localized PC is generally treated by surgical removal or radiation therapy, metastatic PC requires systemic therapies—primarily drugs that repress AR activity. While most PCs resist AR targeting by maintaining or amplifying AR signaling, a subset of PC cells is capable of transdifferentiation— a process whereby a differentiated AR-active tumor cell with secretory luminal cell characteristics, change phenotypes with the resultant loss of AR/luminal cell features and the gain of NE attributes that may include alterations in morphology as well as the expression of NE transcription factors and secretory proteins indicative of differentiated NE cell types (25). This process termed neuroendocrine differentiation (NED) is an adaptive mechanism of PC cells to achieve therapy resistance as AR signaling is no longer operative or required for cell survival and proliferation (28). Determining the cellular mechanisms that initiate NED remains an active area of investigation, although studies have shown that loss of tumor suppressor proteins such as PTEN, RB1, TP53 increases the chances of tumors to acquire neuroendocrine like features (96, 97). However, these tumor suppressors appear to function as permissive rather than deterministic factors. While loss of AR activity and attendant enforcement of epithelial lineage is a key feature contributing to NED, the precise molecular switches responsible for gaining NE functions remain to be identified.

While a complete transition from ARPC to NEPC has been shown to occur in patients, detailed autopsy studies have shown that metastatic tumors may comprise heterogeneous populations of ARPC and NEPC that co-exist. Inter- and intra-tumor heterogeneity with respect to tumor cells with ARPC and NEPC phenotypes is well-documented. Notably, other than representing a clear mechanism/pathway for bypassing AR-directed treatment, the role and influence of NE cells in PC pathology, particularly with respect to tumor progression and therapy resistance is not completely understood. This is relevant in view of the potential for NE-associated paracrine and endocrine factors to influence the behavior of non-NE cell types—either locally or distantly. In this context, a previous study reported that the NE cells promoted the growth of castration sensitive LnCaP cells, when grown as a xenograft in castrated mice (98). Further, NE cells were also shown to enhance the migration and metastasis of ARPC cells in the presence of androgen (99). Thus, NEPC cells may promote the continued survival of ARPC cells in an androgen deprived environment possibly through paracrine and endocrine mechanisms (discussed later).
### TABLE 2  Secreted factors from neuroendocrine cells and potential roles in PC pathobiology.

| Symbol | Name                  | Role                                                                 | Reference |
|--------|-----------------------|----------------------------------------------------------------------|-----------|
| CgA    | Chromogranin A        | • Marker for NED                                                       | (54, 55) |
|        |                       | • Elevated serum level is associated with poor prognosis and is inversely correlated with overall survival in men with CRPC. |           |
| CgB    | Chromogranin B        | • Marker for NED                                                       | (56, 57) |
|        |                       | • Involved in PC transdifferentiation                                  |           |
| SYP    | Synaptophysin         | • Marker for NED                                                       | (58)     |
|        |                       | • Detected in circulating tumor cells of CRPC patients and the expression levels directly correlates with abiraterone and enalatamide resistance. |           |
| ENO2   | Enolase 2             | • Isoenzyme of the glycolytic enzyme enolase.                         | (59, 60) |
| SCGN   | Secretaggin           | • Neuroendocrine marker                                               | (61, 62) |
|        |                       | • Correlates with an increased risk of disease relapse after radical prostatectomy |           |
| NPY    | Neuropeptide Y        | • Growth promoting factor in various malignancies.                    | (63)     |
|        |                       | • Key regulator of energy metabolism in PC cells.                     |           |
|        |                       | • NPY neural axis regulates cancer cell survival, metabolism, and therapy resistance. |           |
| CGRP   | Calcitonin-gene related peptide | • Increase invasiveness and promoting tumor growth in bone microenvironment. | (64, 65) |
| CT     | Calcitonin            | • Elevated in advanced prostate cancer along with calcitonin receptor (CTR). | (8) (66, 67) |
|        |                       | • CT-CTR axis promotes PC cell growth, invasion and epithelial-to-mesenchymal transition (EMT). |           |
| NTS    | Neurotensin           | • Expressed in LnCaP cells as a response to androgen-withdrawal.      | (68)     |
|        |                       | • Induces tumor cell transdifferentiation to NE-like cells through (NTSR1/3) signaling. |           |
| AM     | Adrenomedullin        | • Expressed in LnCaP cells as a response to androgen withdrawal and maintains a NE phenotype. | (69) (70) |
|        |                       | • Supports hormone independent tumor growth and neovascularization by supplying/amplifying signals for neangiogenesis and lymphangiogenesis. |           |
| IL8    | Interleukin 8         | • Expressed in both benign and malignant NE cells.                    | (71) (72, 73) |
|        |                       | • Increased expression associated with reduced FOXA1 expression in NEPC cells. |           |
|        |                       | • Paracrine and autocrine effects: cell survival and proliferation, NED. |           |
| GRP    | Gastrin releasing peptide (mammalian homologue of bombesin)       | • Increased expression as a response to androgen withdrawal, activates the GRP/GRP-receptor (GRP-R) pathway, in turn activating the NF-κB and increased levels of AR-splice variant (AR-V7). | (74) (75) |
|        |                       | • GRPR expression also amplifies in CRPC.                              |           |
| SS     | Somatostatin          | • Inhibits cytokine release from immune cells.                       | (76–79)  |
|        |                       | • Somatostatin receptor scintigraphy (SRS) can identify NE features in prostate cancer and identify metastatic lesions. |           |
| VIP    | Vasoactive intestinal peptide | • Increases expression of VEGF.                                    | (80, 81) |
|        |                       | • Increases NE differentiation in LnCaP cells through PKA, ERK1/2 and PI3K signaling. |           |
| VEGF   | Vascular endothelial growth factor | • Increased expression associated with a more aggressive phenotype by aiding in neovascularization of carcinomas. | (82, 83) |
| PTHrP  | Parathyroid hormone related protein | • Increased metastasis to lymph nodes                               |           |
|        |                       | • Enhances proliferation of LnCaP cells at low levels of androgen, by stabilizing the AR protein through tyrosine phosphorylation and preventing ubiquitination. | (84) (85–87) |
|        |                       | • Induces epithelial-to-mesenchymal transition (EMT) in prostate cancer cells along with promoting invasion, tumorigenicity and metastasis. |           |
|        |                       | • Protection of neighboring prostate cancer cells from Docetaxel (Doc) induced apoptosis. |           |
|        |                       | • Positively regulates bone marrow microenvironment, increasing the angiogenic potential and tumor growth. |           |
| HCG    | Human chorionic gonadotropin | • Associated with poor prognosis in PC patients.                     | (88, 89) |
|        |                       | • Promotes cell migration and invasion via promoting ERK1/2 phosphorylation and MMP-2 upregulation in DU145 cells. |           |
| 5-HT   | Serotonin             | • Cell growth factor for PC cells.                                    | (90, 91) |
|        |                       | • Promotes dedifferentiation of LnCaP cells by maintaining an increased level of cAMP. |           |
|        |                       | • Activates MAPK/Erk and PI3K/Akt pathways to induce proliferation, migration, and differentiation. |           |
| CCK    | Cholecystokinin       | • Induced by cysteine protease cathepsin B (CTSB)                     | (92)     |
|        |                       | • Supports self-renewal of PC stem cells (CSCs)                       |           |
Neuroendocrine carcinomas in non-prostate organs and tissues

Neuroendocrine tumors (NETs) are generally classified as neoplasms with both neural- and endocrine-like characteristics, and these malignancies often have the ability to store and secrete different peptides and neuroamines (100). Although rare, NETs can occur anywhere in the body. Some of the common sites of NET occurrence are the GI tract, lungs and pancreas. The definition of NE cells has changed over the years and in many instances their origins are still not clear. The generally accepted criteria for defining NE cells are: (1) production of a neurotransmitter, neuromodulator or neuropeptide hormone, (2) the presence of dense-core secretory granules from which hormones are released by exocytosis, and (3) the absence of axons and synapses (101). This section briefly discusses several of the more common types of NETs, though as noted above, NETs can arise in nearly every organ/tissue in the body and not all are described here, for example neuroblastoma which is a NE tumor type arising almost exclusively in children (102).

Gastric neuroendocrine tumor

These neoplasms are derived from enterochromaffin-like cells (ECL cells) of the gastric mucosa (103). Over the last several years, the incidence of gNETs is increasing, partly due to improved diagnostic techniques (104). gNETs can be clinically functioning (symptomatic) or silent (non-symptomatic) (105). Based on clinicopathological characteristics, and therapeutic and prognostic implications, gNETs are further subdivided into four types (Type I-Type IV) (104): Type I gNET comprise 70-80% of gNETs and are associated with autoimmune chronic atrophic gastritis (103, 106). These patients often suffer from hypergastrinemia (increased gastrin production by G cells) (103). Patients with type I tumors are usually asymptomatic, and the tumors are rarely metastatic (<2%) (106). However, these tumor cells strongly stain positive for NE markers: chromogranin A (CgA) and neuron specific enolase (NSE) (106), but have very low proliferation rates; Type II gNET represent ~7% of gNETs and behave like type I tumors and are caused by gastrinomas. These tumors show an increased staining for CgA compared to the type I tumors and exhibit a higher metastatic potential (103); Type III gNET are aggressive with tissue invasion and metastasis and have a poor prognosis (106). The tumor cells also show a greater frequency of staining for the proliferation marker Ki-67, but are negative for CgA (106); Type IV gNET are very rare, but are highly malignant and exhibit very high Ki67 staining. The tumor cells may lack CgA expression but stain positive for other NE markers such as synaptophysin (SYP) and NSE (106).

Pancreatic neuroendocrine tumors

These are rare neoplasms that represent 1-2% of all pancreatic tumors (107). They were originally thought to arise from the islets of Langerhans, however, evidence suggest an origin from the pluripotent stem cells in the pancreatic ductal/acinar system (108). pNETs produce a range of hormones, including insulin, glucagon, somatostatin, and vasoactive intestinal peptide (VIP) (107). Although most pNETs occur sporadically, about 10% are associated with underlying genetic syndromes including multiple endocrine neoplasia type I (MEN1), type IV (MEN4), von Hippel-Lindau disease (VHL), neurofibromatosis type I (NF1), or tuberous sclerosis complex (TSC) (109, 110). Like the gNETs, pNETs are also classified into functional and non-functional tumors. Functional tumors elicit systemic symptoms through excessive secretion of hormones.

Lung neuroendocrine tumors

These are a heterogeneous family of neoplasms in the lung, that arises from the Kulchitzky cells of the bronchial mucosa (111). They are classified into four distinct histologic variants, namely, typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) (112).

SCLC is the most aggressive form of lung cancer. SCLC was originally thought to arise de novo from resident neuroendocrine lung cells, but recent evidence from model systems suggests alternative cells of origin such as alveolar type 2 cells (113–115). Similar to NEPC, SCLC can also emerge following targeted therapy for lung adenocarcinoma. For example, resistance to epidermal growth factor receptor (EGFR) inhibitors can result through tumor cell transdifferentiation to SCLC phenotypes which no longer depend on EGFR signaling (116). SCLC is well known to produce a variety of paraneoplastic syndromes that result from the production of hormones such as adrenocorticotropic hormone (ACTH) (117).

Notably, SCLC shares a strong similarity of chromatin structure and gene expression with NEPC (118). A detailed study of various small cell neuroendocrine cancers (SCNCs) across multiple tissues, shows that these cancers share a convergence of molecular signatures (119, 120). Further, as tumor cells progress towards a small cell neuroendocrine (SCN) phenotype through transdifferentiation, they become increasingly independent of tissue of origin and cluster with SCNCs derived from different tissue types (120). Progress in the clinical treatment of SCNCs has been very slow and improving the outcomes of these aggressive tumors by exploiting the mechanisms underlying their genesis has yet to be fully realized.
Merkel cell carcinoma

Merkel cells are highly specialized cells located in the epidermis that function as pressure receptors and may originate from neural crest cells or from epidermal progenitors (121). While originally considered to be the cell of origin of MCC, which is also classified as primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin and trabecular carcinoma of the skin, more recent studies indicate that these tumors arise from a Merkel cell precursor or from resident fibroblasts via transdifferentiation (121, 122). Drivers of MCC include the Merkel cell polyoma virus – accounting for ~80% of MCCs, and the combination of TP53 and RB1 loss, which occur in the remainder (123–126). MCCs share many features with NE carcinomas arising in other tissues including the expression of SYP and CGA and the neural transcription factor NEUROD1 (27).

In summary NETs are a diverse group of neoplasms, distinguished by site of origin, degree of aggressiveness and function. Although site-specific, most of the NETs express immunohistochemical markers like CGA and SYP. These tumors also produce a similar range of bioactive compounds or hormones (127) that may influence tumor cells at distant sites or produce pathological host effects that are collectively termed as paraneoplastic syndrome (PNS). A PNS may be endocrine – resulting from a specific hormone produced by the cancer, or immune mediated. Though PNS are rare when considering all human cancers, they occur more frequently in NETs. Several well-characterized PNS results from the secretion of excess hormones such as ACTH and others that produce neurologic alterations due to the production of autoantibodies (117). For most of these NETs, surgery and chemotherapy remain the primary curative option if the cancer is identified while localized to the primary site. This is, however, not feasible in NEPC as most patients do not present with localized, organ-confined disease.

The endocrine and paracrine characteristics of NEPC

Analogous to benign NE cells found in the normal prostate, NEPC cells are also capable of secreting a wide range of neuropeptides and other factors (11, 12, 51). To date, studies defining the role(s) of NEPC derived secreted products with respect to PC pathogenesis and response to treatment are limited, but the published reports indicate the importance of further work in this field. Collectively, more than 20 distinct NEPC-derived secreted factors have been identified that are capable of exerting effects on PC adenocarcinoma (Table 2). Recently, it was discovered that neuropeptide Y has a paracrine effect on PC cells by influencing apoptosis, motility, and resistance to radiation therapy (63). The cytokine Interleukin 8 (IL-8) is produced by NEPC cells and is capable of activating non-NE PC cells via the IL-8 receptor CXCR1 with downstream signaling that is capable of driving androgen-independent proliferation and tumor cell invasion (71) (Figure 2). Adrenomedullin, a multifunctioning peptide, is produced by PC cells after androgen depletion, and exerts autocrine signaling that induces a NE-like transdifferentiation phenotype switch (69). The neuropeptide Bombesin/Gastrin Releasing Peptide (GRP) which is expressed in NEPC, exerts mitogenic effects toward PC cells via bombesin receptor (BB2) signaling and may also contribute to androgen-independent growth (74) (Figure 2).

The NEPC disease state is often associated with metastatic dissemination. Caveolin-1 is an oncogenic membrane protein associated with extracellular matrix organization, cell migration and signaling (128). In prostate cancer cells, caveolin-1 was shown to exert paracrine effects that increase PC proliferative activity aiding in perineural invasion and reduced apoptosis (129). The presence of caveolin-1 in tumor derived exosomes also has a paracrine effect on PC cells, driving the induction of stem cell phenotypes, epithelial- mesenchymal transition, and neuroendocrine differentiation (130). As discussed previously, NEPC cells have been shown to maintain ARPC adenocarcinoma tumor growth after castration, by releasing uncharacterized factors that act to increase AR expression and activity via paracrine and endocrine signaling (98). NEPC cells have also been shown to promote the development of adenocarcinoma pulmonary metastasis (99). Gelsolin is a multifunctional actin-binding protein (131), that shows an increased expression as a response to extracellular factors produced by NEPC cells. Gelsolin overexpression promotes epithelial cell invasion and an increase in cell migration (99).

As mentioned before, NEPC cells can also exert systemic effects through PNS. Though overall extremely rare, a range of PNSs have been shown to arise in the context of aggressive and metastatic PC, and notably NEPC [reviewed by Hong et al. (132)]. Though unusual, the following paraneoplastic syndromes have been attributed to PC: (1) The syndrome of inappropriate antiidiuretic hormone secretion (SIADH) is a cause of hyponatremia (133). Patients with SIADH have an elevated antidiuretic hormone (ADH) level in the serum, which then acts on the distal tubules and collecting ducts of the nephron and in turn increase water resorption (132). Although SIADH is very rare in PC patients, there have been a few clinical cases reported (133), and PC tumor cells have been shown to express ADH (134). (2) Cushing’s syndrome is caused by an excess of circulating serum cortisol as a result of excess adrenocorticotropic hormone (ACTH) (132). In PC, Cushing’s syndrome is primarily associated NE-differentiation to small cell carcinoma (135). (3) Humoral hypercalcemia, is caused by the inappropriate release of parathyroid hormone related peptide (PTHrP) by the tumor cells, which stimulates bone resorption throughout the skeletal system (132). Although very rare in typical PC, NEPC cells have been reported to synthesize and secrete PTHrP.
with both paracrine signaling effects toward ARPC and endocrine effects contributing to hypercalcemia (84, 136). Several other syndromes resulting from autoimmune responses have been reported in rare instances to be associated with PC and NEPC including Evan’s syndrome which involves immune-mediated hemolytic anemia and thrombocytopenia (137); exfoliative dermatitis (138); polymyalgia rheumatica (139); myasthenia gravis (140); dermatomyositis (141); paraneoplastic jaundice (142) and others (132).

Role of nerves in the development of prostate cancer

In addition to the potential for NE cells to exert effects on non-NE tumor cells via paracrine and/or endocrine effects, nerve cells have also been shown to influence tumor cell behaviors. This section will briefly summarize what is known regarding the role of neural signaling in prostate cancer progression (Figure 3). In addition to fibroblasts, endothelial cells and immune cells, neurons and nerve fibers are integral and functional components of tumor microenvironments (143). The processes of neurogenesis (increased numbers of neurons/nerves) and axonogenesis (tumor induced neural sprouting within or toward tumor microenvironments) can be driven by neurotrophic growth factors released by cancer cells and are emerging as hallmarks of aggressive cancer types (143, 144). The involvement of nerves in cancer has been studied in the context of perineural invasion (PNI), which is the process of neoplastic invasion of nerves contributing to metastatic spread (145, 146). However, until recently, nerves were generally considered passive components of cancers (144). Studies from multiple cancer models have now demonstrated the active involvement of the parasympathetic nervous system (PSNS) and sympathetic nervous system (SNS) in cancer progression and tumorigenesis (147). PSNS and SNS are components of the autonomic nervous system. SNS controls the “fight or flight” response and PSNS controls the “rest and digest” processes. Cholinergic fibers of the PSNS transmits impulses to other nerve cells or muscle fibers by transmitting acetylcholine. Adrenergic fibers of the SNS regulates the function of nearby and distant muscles and also components of the central nervous system by transmitting epinephrine or norepinephrine.

Several landmark studies regarding tumor innervation and its effect in PC have been reported in the last several years and have been reviewed in-depth (144, 148, 149). In-vitro co-culture experiments with dorsal root ganglia showed an increased proliferation of human PC cell lines (150), suggesting an interdependence of carcinoma cells and neurons in PNI contributing to PC progression. The importance of nerves in PC progression was further confirmed when surgical denervation showed inhibition of prostate tumor development in mouse models (151). The same group also parsed out the roles of the two distinct autonomic nerve types: (i) adrenergic fibers of the SNS in promoting tumor cell survival and establishing the initial stages of cancer development by acting through the β2 and
β3-adrenergic receptors, and (ii) cholinergic fibers of PSNS in supporting tumor cell invasion, migration and distant metastases through stromal Chrm1 (cholinergic receptor muscarinic 1)-mediated signals (151). In alignment with these findings, clinical evidence has demonstrated that patients with spinal cord injuries resulting in functional denervation of the prostate have lower incidence rates of PC (152).

The mechanisms by which nerves influence the pathogenesis of solid tumors is beginning to be understood. Tumors rely on angiogenesis to expand beyond certain physiological constraints relating to oxygenation and the delivery and elimination of metabolites (153). Adrenergic nerve fibers release noradrenaline into the tumor microenvironment that stimulates β2-adrenergic receptor expression, resulting in the activation of endothelial cells and angiogenesis, which in turn supports PC growth (154). PCs of higher Gleason grade have been reported by exhibit greater innervations than PCs of lower grade or benign prostatic hyperplasia (144). Various neurotrophic growth factors produced by cancer cells can contribute to the increased axonogenesis in PC. Overexpression of the precursor of nerve growth factor (proNGF) has been reported in PC accompanied by increases in nerve density (155). Furthermore, it was shown that granulocyte colony-stimulating factor (G-CSF) supports the survival of sympathetic nerve fibers and promotes aberrant outgrowth of parasympathetic nerve fibers in PC models (156).

Several studies have evaluated the role of nerve growth factor (NGF) in the development of CRPC and NEPC disease states. Tropomyosin receptor kinase A (TrkA) receptors activated via nerve growth factor (NGF) signaling have been shown to mediate proliferation, invasiveness and epithelial-mesenchymal transition (EMT) in CRPC cells (157). In the context of ARPC treatment resistance, ADT has been shown to activate the transcription factor ZBTB46, which consequently regulates the activation of NGF. NGF in turn promotes NEPC differentiation by interacting with Chrm4 (cholinergic receptor muscarinic 4) (158). Another recent study reported that patients who subsequently developed metastatic CRPC had elevated adrenergic nerve fiber innervation in the primary prostate tumors. High levels of the neurotransmitter norepinephrine, which is produced by sympathetic nerves, was shown to induce NE-like alterations in PC cells, and these effects were effectively inhibited by β2-adrenergic receptor blocker propranolol (159).

**Conclusions and future directions**

Neuroendocrine prostate cancer, whether developing de novo, or through transdifferentiation, carries a very poor prognosis with rapid disease progression and very limited survival. As the frequency of metastatic NEPC appears to be increasing in the setting of more potent AR pathway blockade, new treatment approaches are needed. A notable feature of NE tumors involves their ability to exert effects toward other tumor cell types and benign host cells through endocrine and paracrine mechanisms. These secreted proteins provide a communication network between cancer cells and their adjacent microenvironment that may serve
to drive tumor progression and treatment resistance. Preclinical studies have identified the potential therapeutic benefit of inhibiting the activity of the signaling pathways activated by these NE-derived molecules. However, the full repertoire of NEPC-derived secreted factors – the secretome - remains to be identified and characterized. A recent comprehensive secretome study of different subtypes of SCLC underscores the benefit of understanding the aspects of tumor biology that have extracellular influence (160). A thorough understanding of the NEPC secretome: individual factors and combinations - has the potential to widen our understanding of peptides/proteins that can act in an endocrine/paracrine manner to create tumor macro- and microenvironments conducive to tumor survival and growth. Characterizing the interactions between NEPC and ARPC cells also has the potential to identify key drivers of cancer progression and therapy resistance that could serve as effective targets for future drug development.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Author contributions

Writing and editing of the manuscript, TA and PN. All authors contributed to the article and approved the submitted version.

References

1. Culp MB, Soerjomataram I, Eltahhan JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. *Eur Urol* (2020) 77(1):38–52. doi: 10.1016/j.eururo.2019.08.005
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin* (2022) 72(1):7–33. doi: 10.3322/caac.21708
3. Glandon DF. Histologic grading of prostate cancer: a perspective. *Hum Pathol* (1992) 23(3):273–9. doi: 10.1016/0046-8177(92)90108-F
4. Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. *J Clin Oncol* (2012) 30(6):644–6. doi: 10.1200/JCO.2011.39.1300
5. Craft N, Sawyers CL. Mechanistic concepts in androgen-dependence of prostate cancer. *Cancer Metastasis Rev* (1998) 17(4):421–7. doi: 10.1023/A:1006141806801
6. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. *J Clin Oncol* (2005) 23(32):8253–61. doi: 10.1200/JCO.2005.03.4777
7. Fine SW. Neuroendocrine tumors of the prostate. *Mod Pathol* (2018) 31(S1):S122–32. doi: 10.1038/modpathol.2017.164
8. di Sant’Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. *Hum Pathol* (1992) 23:287–96. doi: 10.1016/0046-8177(92)90110-O
9. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. *Prostate* (1999) 39(2):135–48. doi: 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROSF3.0.CO;2-S
10. Szczryba J, Niessen A, Wagner M, Wandersnooth PM, Aumuller G, Wennemuth G. Neuroendocrine cells of the prostate derive from the neural crest. *J Biol Chem* (2017) 292(5):2021–31. doi: 10.1074/jbc.M116.755082
11. Sun Y, Niu J, Huang J. Neuroendocrine differentiation in prostate cancer. *Am J Transl Res* (2009) 1(2):148–62
12. Butler W, Huang J, Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms. *Precis Clin Med* (2021) 4(1):25–34. doi: 10.1093/pmcmed/pbab003
13. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrra J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nat Med* (2016) 22(3):298–305. doi: 10.1038/nm.4045
14. Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. *J Clin Invest* (2019) 129(10):4492. doi: 10.1172/JCI128212
15. Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. *Science* (2017) 355(6320):84–8. doi: 10.1126/science.aah4307
16. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. *Science* (2017) 355(6320):78–83. doi: 10.1126/science.aah4199

Funding

We gratefully acknowledge support from the Pacific Northwest Prostate Cancer SPORE CA097186; NCI R01 CA234715, IR01 CA266452, PC170350P1, the Prostate Cancer Foundation and the Institute for Prostate Cancer Research.

Acknowledgments

We thank members of the Nelson laboratory, John Lee and Michael Haffner for helpful comments and suggestions.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
determined by the subcellular distribution of the androgen receptor. Cancer Discov (2011) 1(6):487–95. doi: 10.1158/2155-8290.CD-11-0330

30. Beltran H, Tagawa ST, Park K, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2012) 30(36):e368–9. doi: 10.1158/2155-8290.CD-11-0330

31. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConkey BJ, Brahmbhatt S, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 227(3):286–97. doi: 10.1002/path.4047

32. Erickson LA, Lloyd RV. Practical markers used in the diagnosis of endocrine prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2018) 21:145–51. doi: 10.1038/s41391-018-0046-9

33. Sugimura Y, Cunha GR, Donjacour AA. Morphogenesis of ductal networks in the mouse prostate. Acta Histochem Suppl (1990) 38:127–32.

34. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, et al. NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Cytol Histol Oncol (2013) 33(1):57–65. doi: 10.3250/3300131824.77317.a7

35. Henry GH, Malewska A, Joseph DB, Malladi VS, Lee J, Torrealba J, et al. A paracrine cell to cell proliferation in normal, hyperplastic, and neoplastic human prostates. Cell Prolif (2018) 51(3):e12419. doi: 10.1111/cpr.12419

36. Abdulrahman F, Hamad Z, Gao J, Wei J, Li N, Wang L, et al. Functional and clinical validation of new biomarkers for prostate cancer. J Clin Med (2022) 11(7):2096. doi: 10.3390/jcm11072096

37. Ginestier C, Delattre O, Brown M, Voulanakis E, Lindeman GJ, Charafe-Jauffret E, et al. Clonal evolution in breast cancer revealed by single-cell gene expression analysis. Nat Biotechnol (2010) 28(6):559–63. doi: 10.1038/nbt.1863

38. Bonollo F, Thalmann GN, Kruithof-de Julio M, Karkampoussa S. The role of cancer-associated fibroblasts in prostate cancer tumorigenesis. Cancers (Basel) (2020) 12(7):1887. doi: 10.3390/cancers12071887

39. Troján L, Thomas D, Friedrich D, Grobholz R, Knoll T, Allen P, et al. Expression of different vascular endothelial markers in prostate cancer and RBP4 tissue: an immunohistological and clinical evaluation. Anticancer Res (2004) 24(3A):1561–6. doi: 10.2187/ajrccm.165.6.1561

40. Bates M, Kovalenko B, Wilson EL, Moscatelli D. Endothelial cells support the growth of prostate tissue in vivo. Prostate (2008) 68(8):893–901. doi: 10.1002/pros.20762

41. Alsaad B, Besede T, Karam I, Abd-Alsamad I, Uhl JF, Benso G, et al. Coexistence of adrenergic and cholinergic nerves in the inferior hypogastric plexus: anatomical and immunohistochemical study with 3D reconstruction in human male fetus. J Anat (2009) 215(4):453–64. doi: 10.1111/j.1469-7580.2009.01171.x

42. Cao J, Zhuo X, Zhao X, Li X, Xu R. Neutrophil-to-Lymphocyte ratio predicts PSA response and prognosis in prostate cancer: A systematic review and meta-analysis. PLoS One (2011) 6(7):e20577. doi: 10.1371/journal.pone.0020577

43. Dang T, Liu YG. Macrophage cytokines enhance cell proliferation of normal prostate epithelial cells through activation of ERK and akt. Sci Rep (2018) 8(1):7718. doi: 10.1038/s41598-018-26143-8

44. Kurtia T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the prostate. Development (2004) 131(20):4955–64. doi: 10.1242/dev.013881

45. Zang D, Zhao S, Li X, Kirk JS, Tang DG. Prostate luminal progenitor cells in development and cancer. Trends Cancer (2018) 4(1):769–83. doi: 10.1016/j.trecan.2018.09.003

46. Joseph DB, Turco AF, Vezina CM, Strand DW. Progenitors in prostate development and disease. Dev Biol (2021) 473:50–8. doi: 10.1016/j.devbx.2020.11.012

47. Joseph DB, Henry GH, Malewska A, Reese JC, Mauck RJ, Gahan JG, et al. Single-cell analysis of mouse and human prostate reveals novel fibroblasts with specialized distribution and microenvironment interactions. J Pathol (2021) 255(2):141–54. doi: 10.1002/path.5751

48. Falkiner S, Askenson U, Grimelius L, Abrahamsson PA. Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of the prostate gland during tumour progression. Acta Histochim Suppl (1990) 38:127–32.

49. Bonkhoff H, Wernert N, Dhom G, Remmber K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate (1994) 21(2):91–8. doi: 10.1002/pros.2990190202

50. Bonkhoff H, Stein U, Remmber K. Endocrine-paracrine cell types in the prostate and prostate adenocarcinoma are postmitotic cells. Hum Pathol (1995) 26(2):167–70. doi: 10.1006/path.1995.0003-0

51. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl (2004) 6:1–38. doi: 10.1002/pros.20045

52. Grigore AD, Ben-Jacob E, Farach-Carson MC. Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? Front Oncol (2015) 5:37. doi: 10.3389/fonc.2015.00037

53. Huang J, Wu C, di Sant'Agnese PA, Yao J, Cheng L, Na Y. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Annu Cyclist Histol (2007) 29(3):128–38.

54. Giridhar, et al. Serum chromogranin-a-based prognosis in metastatic hormone-refractory prostate cancer. Eur J Cancer (2011) 47:749–56. doi: 10.1016/j.ejca.2011.07.013

55. Guo, et al. Chromogranin a is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis. Cancer Manage Res (2019) 11:2747. doi: 10.2147/CMAJ.S190678

56. Pruneri, et al. Chromogranin a and b and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate (1998) 34(2):113. doi: 10.1002/(SICI)1097-0045(199802)34:2<113::AID-PRO2>3.0.CO;2-T

57. Yuan, et al. Androgen deprivation induces human prostatic epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocrine-Related Cancer (2006) 13(1):151. doi: 10.1677/erc.1.01143

58. Pal, et al. Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide. Urologic Oncology: Semin Original Investigations (2018) 36(4):162.e1. doi: 10.1016/j.urolonc.2017.12.006

59. Ingo, et al. Neuron-specific enolase as a biomarker: Biochemical and clinical aspects. Adv Exp Med Biol (2015) 867:125. doi: 10.1007/978-94-017-7125-0_9

60. Kim, et al. FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene (2017) 36(28):4072. doi: 10.1038/onc.2017.50

61. Abdol, et al. Secretogranin is a new neuroendocrine marker in the human prostate. Prostate (2007) 67(5):472. doi: 10.1002/pros.20523
82. Flores-Morales, et al. Proteoglycan characterization of patient- derived xenografts highlighting the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer. *Clin Cancer Res* (2019) 25(2):595.

doi:10.1158/1078-0432.CCR-18-0729

83. Ding Y, Lee M, Gao Y, Bu P, Coara C, Miles B, et al. Neuroepithetip y nerve paracrine regulation of prostate cancer oncogenesis and therapy resistance. *Prostate* (2021) 81(1):58–71. doi:10.1002/pros.24081

84. Nagakawa, et al. Effect of prostate neuropeptides on invasion and migration of PC-3 prostate cancer cells. *Cancer Lett* (1998) 133(1):27. doi:10.1016/S0304-3835(98)00186-4

85. Zhu, et al. Neuronal calcitonin gene-related peptide promotes prostate tumor growth in the bone microenvironment. *Peptides* (2021) 135:170423.
doi:10.1016/j.peptides.2020.170423

86. Shah, et al. Calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways. *Endocrine-Related Cancer* (2008) 15(4):953. doi:10.1677/ERC-08-0136

87. Aldaikash, et al. Calcitonin induces stem cell-like phenotype in prostate cancer cells. *Endocrine-Related Cancer* (2019) 26(11):815. doi:10.1530/ERC-19-0333

88. Boules, et al. Diverse roles of neurotransphins in the central nervous system. *Front Endocrinol* (2013). doi:10.3389/fendo.2013.0036

89. Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, et al. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates ‘neuroendocrine phenotype’ in LNCaP prostate tumor cells. *Oncogene* (2007) 26(4):506–18. doi:10.1038/onc.2005.656

90. Berenguer-Daiz, et al. Adrenomedullin blockade suppresses growth of human hormone-independent prostate tumor xenograft in mice. *Clin Cancer Res* (2013) 19(22):6138. doi:10.1158/1078-0432.CCR-12-0691

91. Huang J, Yao J, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. *Am J Pathol* (2005) 166(6):1807–15. doi:10.1016/S0002-9440(05)62490-X

92. Guo, et al. IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-kB pathway in prostate cancer. *Mol Med Rep* (2017) 16(6):9305. doi:10.3892/mmr.2017.7747

93. Mok, et al. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. *J Exp Clin Cancer Res* (2022) 41(1):46.
doi:10.1186/s13046-022-02255-y

94. Qiao J, Grabowska MM, Forester-Roman JS, Mironевич J, Case TC, Chung HK, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. *Am J Pathol* (2005) 166(6):1807–15. doi:10.1016/S0002-9440(05)62490-X

95. Dizeyi, et al. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. *Urologic Oncology: Semin Original Investigations* (2011) 29(4):436. doi:10.1016/j.urolonc.2009.09.013

96. Shinka, et al. Serotonin synthesis and metabolism–related molecules in a human prostate cancer cell line. *Oncol Lett* (2011) 2(2):211. doi:10.3892/ol.2011.244

97. Tang, et al. Adipocytes promote prostate stem cell self-renewal through amplification of the cholecystokinin autocrine loop. *Oncotarget* (2016) 7(4):4399. doi:10.18632/oncotarget.6643

98. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. *N Engl J Med* (2005) 353(4):366–81. doi:10.1056/NEJMra0311526

99. Knudsen BS, Vassoukhin V. Mechanisms of prostate cancer initiation and progression. *Adv Cancer Res* (2010) 101:99–51. doi:10.1016/B978-0-12-380890-5.00001-6

100. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. *Genes Dev* (2000) 14(19):2410–34. doi:10.1101/gad.819500

101. Kelly, B K. Reprogramming to resist. *Science* (2017) 355(6320):29–30. doi:10.1126/science.aam3535

102. Sinha S, Nelson P5. The path of most resistance: Transdifferentiation underlies exceptional nonrespondes to androgen receptor pathway inhibition in prostate cancer. *Cancer Discov* (2017) 7(7):673–4. doi:10.1158/2159-8290.CD-17-0483

103. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. *Cancer Res* (2014) 74(15):5489–95. doi:10.1158/0008-5472.CAN-13-3117

104. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matsui RJ, et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. *Prostate* (2006) 66(5):336–45. doi:10.1002/prro.20369

105. Vinik AJ, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseam GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. *Pancreas* (2010) 39(6):713–34. doi:10.1097/MPA.0b013e3181e81ba7f

106. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. *Endocr Pathol* (2004) 15(1):1–18. doi:10.1210/jc.2003-031575

107. McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. *World J Gastroenterol* (2013) 19(22):6574. doi:10.3748/wjg.v20.11.118

108. Carvajal JR, Danis-Ribeiro M, Pimentel-Nunes P, Libanio D. Neuroendocrine tumors of the gastrointestinal tract: A focused review and practical approach for gastroenterologists. *GE Port J Gastroenterol* (2021) 28(5):336–48. doi:10.1590/0102-672020170020016

109. Díaz AR, Azevedo BC, Alban LBV, Yagi OK, Ramos M, Jacob CE, et al. Gastric neuroendocrine tumor: Review and update. *GE Port J Gastroenterol* (2021) 28(5):336–48. doi:10.1590/0102-672020170020016

110. Arq Bras Cir Dig (2017) 30(2):150–4. doi:10.1590/0102-672020170020016

111. Doi, et al. Gastric neuroendocrine tumor: A focused review and practical approach for gastroenterologists. *GE Port J Gastroenterol* (2021) 28(5):336–48. doi:10.1590/0102-672020170020016

112. Oberg KE. Gastrointestinal Neuroendocrine Tumors. *Annals of Oncol* (2010) 21 Suppl 7:v72–80. doi:10.1093/annonc/mdg290

113. Li, et al. Gastric neuroendocrine tumor. *World J Gastroenterol* (2021) 28(5):336–48. doi:10.3748/wjg.v20.11.118

114. McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. *Gastro Oncology* (2014) 7:3(5):336–48. doi:10.18632/oncoline.2009.09.013

115. Yoshida S, Yakanai E, White CM, Zhong Y, Saunders T, Morgan R, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well differentiated pancreatic neuroendocrine tumors. *Am J Surg Pathol* (2012) 36(2):173–84. doi:10.1097/PAS.0b013e32817417e6
110. de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol (2012) 9(4):199–208. doi: 10.1038/nrgastro.2012.9
111. Chung S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics (2006) 26(1):41–57. doi: 10.1148/radiographics.261.1.16055057
112. Polorato, Sonzogni A, Hartai S, Albinia A, Bressola E, Marchio C, et al. Classification of pulmonary neuroendocrine tumors: new insights. Transl Lung Cancer Res (2017) 6(5):513–29. doi: 10.21037/tlcr.2017.09.04
113. Park KS, Liang MC, Raiser DM, Zampioni R, Roach RR, Curtis SJ, et al. Characterization of the cell of origin for small cell lung cancer. Cell Cycle (2011) 10 (16):2806–15. doi: 10.4161/cc.10.16.17012
114. Sutherland KD, Proost N, Brouns I, Adriaenssens D, Song IY, Berna A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell (2011) 19(6):754–64. doi: 10.1016/j.ccell.2011.04.019
115. Ferone G, Song IY, Krijgsman O, van der Vliet J, Coulinjay M, Semonova EA, et al. FGFR1 oncogenic activation reveals an alternative cell of origin of SCLC in Rb1/p53 mice. Cell Rep (2020) 30(11):3837–50 e3. doi: 10.1016/j.celrep.2020.02.052
116. Ozer MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Cancer Oncol (2015) 1(6):e165–72. doi: 10.1016/j.2045-11805
117. Soomro Z, Youssef M, Yust-Katz S, Jalali A, Patel AJ, Mandel J. Paraneoplastic syndromes in small cell lung cancer. J Thorac Dis (2020) 12 (10):6253–63. doi: 10.21037/jtd.2020.03.88
118. Cejas P, Xie Y, Font-Tello A, Lim K, Syama, S Qiu, X, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun (2021) 12(1):5775. doi: 10.1038/s41467-021-26042-z
119. Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science (2018) 362(6410):91–5. doi: 10.1126/science.aat5749
120. Balanis NG, Sheu KM, Eedehe FN, Patel SJ, Smith BA, Park JW, et al. Paraneoplastic syndromes in small cell lung cancer: a comprehensive review. J Thorac Dis (2020) 12 (10):6253–63. doi: 10.21037/jtd.2020.03.88
121. Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbe C, Veness M, et al. Merkel cell carcinoma. Nat Rev Dis Primers (2017) 3:17077. doi: 10.1038/nrdp.2017.77
122. Dika E, Pellegrini C, Lambertini M, Patriti A, Venture A, Baraldi C, et al. Merkel cell carcinoma: an updated overview of clinico-pathological aspects, molecular genetics and therapy. Eur J Dermatol (2021) 31(6):691–701. doi: 10.10684/edpl.2021.4170
123. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol (2005) 89(1):1–4. doi: 10.1002/jso.20167
124. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyoma virus in human Merkel cell carcinoma. Science (2008) 319(5866):1096–100. doi: 10.1126/science.1152586
125. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Albores-Saavedra J, et al. Pancreatic neuroendocrine tumors: from genetics to therapy. JNCI Cancer Discov (2020) 10(3):641–50. doi: 10.1016/j.jnci.2020.07.004
126. Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, et al. Multimodal landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinoomas with implications for immunotherapy. Oncotarget (2015) 7(5):3403. doi: 10.18632/onc(target.6494
127. Oromsky B, Ma PC, Moenssens D, Carter CA. Nothing but NET: A review of neuroendocrine carcinomas and neuroblastomas. Neoplasia (2017) 19(12):991–1002. doi: 10.1016/j.neo.2017.09.002
128. Nywosz ZC, Ebert MP, Dooley S, Meyer C. Caveolin-1 in the regulation of cell metabolism: a cancer perspective. Mol Cancer (2016) 15(1):71. doi: 10.1186/s12943-016-0558-7
129. Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolow A, Chakraborty S, et al. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate (2001) 49(3):213–23. doi: 10.1002/pros.10013
130. Maughn C, Hall SJ, Lin J, Xue X, Berber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science (2013) 341(6142):1236361. doi: 10.1126/science.1236361
131. Rydberg SM, Drapkin R. Tumor innervation: peripheral nerves take control of the tumor microenvironment. J Clin Invest (2021) 131(11):e147276. doi: 10.1172/JCI147276
132. Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolow A, Chakraborty S, et al. In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate (2001) 49(3):213–23. doi: 10.1002/pros.10013
133. Follman J, Watson K, Inger D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature (1989) 340(6229):58–61. doi: 10.1038/340586a0
134. Zakhala AH, Narain-Estape A, Maryanovich M, Nakahara F, Cruz CD, Finlay LWS, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science (2017) 358(6361):321–6. doi: 10.1126/science.aah5072
155. Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al. ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer. *Am J Pathol* (2014) 184(12):3156–62. doi: 10.1016/j.ajpath.2014.08.009

156. Dobrenis K, Gauthier LR, Barroca V, Magnon C. Granulocyte colony-stimulating factor off-target effect on nerve outgrowth promotes prostate cancer development. *Int J Cancer* (2015) 136(4):982–8. doi: 10.1002/ijc.29046

157. Di Donato M, Cernera G, Migliaccio A, Castoria G. Nerve growth factor induces proliferation and aggressiveness in prostate cancer cells. *Cancers (Basel)* (2019) 11(6):784. doi: 10.3390/cancers11060784

158. Chen WY, Wen YC, Lin SR, Yeh HL, Jiang KC, Chen WH, et al. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. *Commun Biol* (2021) 4(1):22. doi: 10.1038/s42003-020-01549-1

159. Dwivedi S, Bautista M, Shrestha S, Elhasasna H, Chaphekar T, Vizeacoumar FS, et al. Sympathetic signaling facilitates progression of neuroendocrine prostate cancer. *Cell Death Discovery* (2021) 7(1):364. doi: 10.1038/s41420-021-00752-1

160. Wang XD, Hu R, Ding Q, Savage TK, Huffman KE, Williams N, et al. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells. *Nat Commun* (2019) 10(1):3201. doi: 10.1038/s41467-019-11153-5